106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2021 All rights reserved
Disclaimer
is pocket guide is derived om recommendations in the American Society of Clinical Oncolog y
Guideline. is resource is a practice tool based on ASCO
®
practice guidelines and is not intended
to substitute for the independent professional judgment of the treating physician. Practice guidelines
do not account for individual variation among patients. is pocket guide does not purport to suggest
any particular course of medical treatment. Use of the practice guidelines and this resource are
voluntary. e practice guidelines and additional information are available at www.asco.org/breast-
cancer-guidelines. Copyright © 2021 by American Society of Clinical Oncolog y. All rights reserved.
ASCOHER11214b
Abbreviations
ASCO, American Society of Clinical Oncology; CCO, Cancer Care Ontario; DFS, disease-
free survival; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; IV,
intravenous; OS, overall survival; TAILORx, Trial Assigning Individualized Options for Treatment
Source
Giordano SH, Freedman RA, and Somerfield MR. Abemaciclib with Endocrine erapy in the
Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and
Targeted erapy Guideline Rapid Recommendation Update. J Clin Oncol. 2021 Dec 8.
doi: 10.1200/JCO.21.02677
Denduluri N, Somerfield MR, Chavez-MacGregor M, et al. Selection of Optimal Adjuvant
Chemotherapy and Targeted erapy for Early Breast Cancer: ASCO Guideline Update.
J Clin Oncol. 2021 Feb 20;39(6):685-693.
Denduluri N, et al. Selection of Optimal Adjuvant Chemotherapy and Targeted erapy for
Early Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused
Update. J Clin Oncol. 2018 May 22;36(23): 2433-2443.
Denduluri N, et al. Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal
Growth Factor Receptor 2 (HER2)-Negative and Adjuvant Targeted erapy for HER2-Positive
Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer
Care Ontario Clinical Practice Guideline. J Clin Oncol. 2016 Jul 10;34(20):2416-2427.
Eisen A, Fletcher GG, Gandhi S, et al. Optimal systemic therapy for early breast cancer in women:
A clinical practice guideline. Curr Oncol. 22:S67-S81, 2015 (suppl 1).
ASCO believes that cancer clinical trials are vital to inform medical decisions and
improve cancer care and that all patients should have the opportunity to participate.
Additional information, which may include data supplements, slide sets, patient
versions, frequently asked questions, and other clinical tools and resources, is available at
www.asco.org/breast-cancer-guidelines
